Cancer Drug Parity Act of 2021
Summary
Cancer Drug Parity Act of 20 21 This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration. To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jul 2021
Committee Review
Floor Vote
President
Introduced Jul 9, 2021
Last action Jul 9, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Jul 9, 2021
Committee
Referred to the House Committee on Education and Labor.
lower
Jul 9, 2021
Introduced
Introduced in House
lower
1 primary · 36 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Brian Higgins
DDemocratic
Co
Alan S. Lowenthal
DDemocratic
Co
Ann M. Kuster
DDemocratic
Co
Brett Guthrie
RRepublican
Co
Brian K. Fitzpatrick
RRepublican
Co
Carolyn B. Maloney
DDemocratic
Co
Chellie Pingree
DDemocratic
Co
Colin Z. Allred
DDemocratic
Co
David J. Trone
DDemocratic
Co
Don Young
RRepublican
Co
Doris O. Matsui
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 4385
Scope: US
Hi! I can help you understand HR 4385. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline